Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 3
1(50.0%)
2Total
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07240753Not Yet Recruiting

A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma

Role: collaborator

NCT04384627Phase 3Active Not Recruiting

Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy

Role: collaborator

NCT00941538Not ApplicableUnknown

Cluster Randomized Controlled Screening Trial for NPC

Role: collaborator

All 3 trials loaded